Abstract: This invention relates to 9-thia-, 9-oxothia, and 9-dioxothia-11,12-seco-prostaglandins and processes for their manufacture. These compounds have prostaglandin-like biological activity and are particularly useful for the treatment of skin diseases such as psoriasis, for the prevention of Thrombus formation, in stimulating the production of growth hormone in intact animals, and as regulators of the immune response.

Abstract: Use of phosphorous acid (H.sub.3 PO.sub.3) and zinc to inhibit the corrosion of metals by oxygen-bearing waters.

Abstract: A method of inhibiting corrosion and scale formation in an aqueous system is disclosed which comprises the step of treating the said system with 0.1 to 500 parts per million by weight of the total aqueous content of the said system, of a composition which comprises amine adducts of maleic anhydride polymers and which may additionally include zinc.

Abstract: Improved cementing compositions and their use in cementing operations is disclosed, wherein copolymers of hydrolyzed acrylamide and 2-acrylamido-2-methylpropane sulfonic acid derivatives are used as fluid loss additives for aqueous hydraulic cement slurries.

Abstract: Methods of using aqueous hydraulic cement compositions containing polyamido-sulfonic compounds as flow-property-improving and turbulence-inducing additives are disclosed.

Abstract: Alcohols, particularly anhydrous alcohols, thickened with aminomethylated polyacrylamide, used as fracturing fluids for stimulating well production.

Abstract: Racemic or optically-active prostaglandin E.sub.1 is synthesized from racemic or optically-active precursors in good yield at the various steps from 3.alpha.,6,7,7.alpha.-tetrahydro-4-methyl-2-oxo-1.beta.-indaneheptanoic acid methyl ester proceeding through 2.alpha.-(2-carboxyethyl)-3.beta.-hydroxy-5-oxo-1.beta.-cyclopentaneheptan oic acid methyl ester, .delta.-lactone, 5-cyclic ethylene acetal, 2.alpha.-(2-carboxy-2-formylethyl)-3.beta.-hydroxy-5-oxo-1.beta.-cyclopent aneheptanoic acid methyl ester, .delta.-lactone, 5-cyclic ethylene acetal, 2.alpha.-(2-carboxy-2-oxoetyl)-3.beta.-hydroxy-5-oxo-1.beta.-cyclopentaneh eptanoic acid methyl ester, .delta.-lactone, 5-cyclic ethylene acetal, and 3.beta.-hydroxy-2.alpha.-(3-oxo-1-octenyl)-5-oxo-1.beta.-cyclopentanehepta noic acid methyl ester, 5-cyclic ethylene acetal.

Abstract: Novel di-bicyclo[3.1.1] and [2.2.1]heptyl and dibicyclo[3.1.1] and [2.2.1]heptenyl ketones are useful as intermediates for preparing novel polyamines useful as antimicrobial agents, as well as algae inhibitors.

Abstract: Water-soluble segmented polymers of the ##STR1## A--B--A, and (A--B).sub.n types wherein the A-segments are grafted homopolymer, copolymer and/or terpolymer segments of water-soluble vinyl monomers, and the B-segments are homopolymer segments of poly(vinyl pyrrolidone) or poly(vinyl alcohol), are prepared by a process employing inverse emulsion techniques and cerium (IV) salt initiators.

Abstract: Racemic or optically-active prostaglandin E.sub.1 is synthesized from racemic or optically-active precursors in good yield at the various steps from 3.alpha.,6,7,7.alpha.-tetrahydro-4-methyl-2-oxo-1.beta.-indaneheptanoic acid methyl ester proceeding through 2.alpha.-(2-carboxyethyl)-3.beta.-hydroxy-5-oxo-1.beta.-cyclopentaneheptan oic acid methyl ester, .delta.-lactone, 5-cyclic ethylene acetal, 2.alpha.-(2-carboxy-2-formylethyl)-3.beta.-hydroxy-5-oxo-1.beta.-cyclopent aneheptanoic acid methyl ester, .delta.-lactone, 5-cyclic ethylene acetal, 2.alpha.-(2-carboxy-2-oxoethyl)-3.beta.-hydroxy-5-oxo-1.beta.-cyclopentane heptanoic acid methyl ester, .delta.-lactone, 5-cyclic ethylene acetal, and 3.beta.-hydroxy-2.alpha.-(3-oxo-1-octenyl)-5-oxo-1.beta.-cyclopentanehepta noic acid methyl ester, 5-cyclic ethylene acetal.

Abstract: In the flocculation and removal of suspended matter from water, combinations of cationic and nonionic water-soluble polymers are found to be more effective than equivalent concentrations of cationics alone, and significantly lower concentrations of the combination are found to be equivalent in effect to higher concentrations of cationic polymers alone.

Abstract: Block polymers of the A-B-A type wherein the A block is derived from a water-soluble monomer and the B block is derived from N-vinyl pyrrolidone. The polymers are water soluble and are useful as flocculants.

Abstract: Racemic or optically-active prostaglandin E.sub.1 is synthesized from racemic or optically-active precursors in good yield at the various steps from 3.alpha., 6,7,7.alpha.-tetrahydro-4-methyl-2-oxo-1.beta.-indaneheptanoic acid methyl ester proceeding through 2.alpha.-(2-carboxyethyl)-3.beta.-hydroxy-5-oxo-1.beta.-cyclopentaneheptan oic acid methyl ester, .delta.-lactone, 5-cyclic ethylene acetal, 2.alpha.-(2-carboxy-2-formylethyl)-3.beta.-hydroxy-5-oxo-1.beta.-cyclopent aneheptanoic acid methyl ester, .delta.-lactone, 5-cyclic ethylene acetal, 2.alpha.-(2-carboxy-2-oxoethyl)-3.beta.-hydroxy-5-oxo-1.beta.-cyclopentane heptanoic acid methyl ester, .delta.-lactone, 5-cyclic ethylene acetal, and 3.beta.-hydroxy-2.alpha.-(3-oxo-1-octenyl)-5-oxo-1.beta.-cyclopentanehepta noic acid methyl ester, 5-cyclic ethylene acetal.

Abstract: The invention relates to a new and novel synthesis of prostaglandin E.sub.2, and it particularly relates to a novel process starting with relatively inexpensive starting materials. The invention further relates to a synthesis which is readily adaptable for large scale processing because of the high yields in the individual reaction steps.The invention further relates to novel compounds formed as intermediates in the synthesis of prostaglandin E.sub.2. The invention still further relates to synthetic analogs and known metabolites of prostaglandin E.sub.2 and prostaglandin E.sub.1, useful as standards in certain biological assays for determining prostaglandin-like activity.

Abstract: Racemic or optically-active prostaglandin E.sub.1 is synthesized from racemic or optically-active precursors in good yield at the various steps from 3.alpha., 6,7,7.alpha.-tetrahydro-4-methyl-2-oxo-1.beta.-indaneheptanoic acid methyl ester proceeding through 2.alpha.-(2-carboxyethyl)-3.beta.-hydroxy-5-oxo-1.beta.-cyclopentaneheptan oic acid methyl ester, .delta.-lactone, 5-cyclic ethylene acetal, 2.alpha.-(2-carboxy-2-formylethyl)-3.beta.-hydroxy-5-oxo-1.beta.-cyclopent aneheptanoic acid methyl ester, .delta.-lactone, 5-cyclic ethylene acetal, 2.alpha.-(2-carboxy-2-oxoethyl)-3.beta.-hydroxy-5-oxo-1.beta.-cyclopentane heptanoic acid methyl ester, .delta.-lactone, 5-cyclic ethylene acetal, and 3.beta.-hydroxy-2.alpha.-(3-oxo-1-octenyl)-5-oxo-1.beta.-cyclopentanehepta noic acid methyl ester, 5-cyclic ethylene acetal.

Abstract: The invention is concerned with novel 16-aryloxy-, 16-alkoxy-, 16-arylthio- and 16-alkylthio-8-aza-9-dioxothia-11,12-seco-prostaglandins and processes for their preparation. These novel compounds are useful as pharmaceuticals since they can be used in animals for estrus synchronization and treatment of infertility due to persistence of luteal function.

Abstract: Racemic or optically-active prostaglandin E.sub.1 is synthesized from racemic or optically-active precursors in good yield at the various steps from 3.alpha.,6,7,7.alpha.-tetrahydro-4-methyl-2-oxo-1.beta.-indaneheptanoic acid methyl ester proceeding through 2.alpha.-(2-carboxyethyl)-3.beta.-hydroxy-5-oxo-1.beta.-cyclopentaneheptan oic acid methyl ester, .delta.-lactone, 5-cyclic ethylene acetal, 2.alpha.-(2-carboxy-2-formylethyl)-3.beta.-hydroxy-5-oxo-1.beta.-cyclopent aneheptanoic acid methyl ester, .delta.-lactone, 5-cyclic ethylene acetal, 2.alpha.-(2-carboxy-2-oxoethyl)-3.beta.-hydroxy-5-oxo-1.beta.-cyclopentane heptanoic acid methyl ester, .delta.-lactone, 5-cyclic ethylene acetal, and 3.beta.-hydroxy-2.alpha.-(3-oxo-1-octenyl)-5-oxo-1.beta.-cyclopentanehepta noic acid methyl ester, 5-cyclic ethylene acetal.

Abstract: This invention relates to 11,12-secoprostaglandins and processes for their manufacture. These compounds have prostaglandin-like biological activity and are particularly useful as renal vasodilators, for the treatment of hypertension, and for the prevention of thrombus formation.

Abstract: This invention relates to 8,10-diaza-9-oxo(and thioxo)-11,12-secoprostaglandins and processes for their manufacture. These compounds have prostaglandin-like biological activity and are particularly useful as renal vasodilators, and for the prevention of thrombus formation.

Abstract: This invention relates to 8-aza-11,12-secoprostaglandins and processes for their manufacture. These compounds have prostaglandin-like biological activity and are particularly useful as renal vasodilators.